Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
116,932,531
-
Total 13F shares
-
104,167,644
-
Share change
-
+5,026,251
-
Total reported value
-
$1,798,715,383
-
Put/Call ratio
-
48%
-
Price per share
-
$17.27
-
Number of holders
-
280
-
Value change
-
+$103,220,845
-
Number of buys
-
144
-
Number of sells
-
115
Institutional Holders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) as of Q3 2025
As of 30 Sep 2025,
Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) was held by
280 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
104,167,644 shares.
The largest 10 holders included
ARK Investment Management LLC, VANGUARD GROUP INC, BlackRock, Inc., MORGAN STANLEY, Contrarius Group Holdings Ltd, STATE STREET CORP, GOLDMAN SACHS GROUP INC, REGENERON PHARMACEUTICALS, INC., BAKER BROS. ADVISORS LP, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
280
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.